TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRalpha and LXRbeta, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRalpha/beta transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders[1].
Molecular Weight:
739.12
Formula:
C38H22ClF3N4O5S
Target:
LXR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
